👉KLTO is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here,

The biotech space is probably the most news-driven of any in the markets.

Today’s “tactical trade” idea is a very stark demonstration of that.

💥Have a look at the chart for Klotho Neurosciences, Inc. (KLTO).

You can see the stock was very sleepy through much of 2025.

Even its post- “Liberation Day” recovery was fairly muted.

Everything changed on June 9, though, when it revealed huge preclinical findings (details below) that sent its stock to the moon 🚀 — up as high as 1,800% within two trading days.

The company raised a lot of money after that by exercising warrants (again, details below), depressing the stock price, but placing it on much more solid financial footing.

The stock is now back to a level that is well worth considering. It made a 10% jump on Friday — indicative of a true reversal — and is up about 3% in the premarket as of this writing.

💥Tune into KTLO today to see if that ramp-up continues.

👉  KLTO is TODAY’S #1 ALERT 👈

1. α-Klotho (s-KL) is an “anti-aging” powerhouse

KLTO has licensed a unique variant of the α‑Klotho gene from the Autonomous University of Barcelona. The gene is found in cells throughout the body and can produce a protein called secreted alpha-Klotho (or s-KL).

s-KL is found mainly in neurons in the brain and spine and is considered neuroprotective thanks to its role in reducing oxidative stress and inflammation.

2. KLTO scored an Orphan Drug Designation for its ALS gene therapy

On July 10, KTLO announced that the FDA has granted an Orphan Drug Designation to KLTO-202 — the company’s novel s-KL promoter, gene and delivery system — for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease.

That means seven years of U.S. market exclusivity, tax credits, waived FDA application fees, and serious validation from the FDA.

3. Preclinical data showed 20% lifespan extension in animal models

The company’s big breakthrough came on June 9 when it revealed findings from pre-clinical studies “indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span.”

The findings found that elevating expression of s‑KL via an AAV9 delivery vector led to a 20% increase in lifespan in mice — alongside the reduction of age-related degeneration in multiple organs.

KLTO stock rocketed nearly 800% the day of the announcement, leading Forbes to ask:

On June 10, the stock roared an additional 115% for an overall peak move of 1,800% in two trading days.

4. Partnering with AAVnerGene for next-gen infrastructure

Last Tuesday, August 12, KLTO tapped AAVnerGene, Inc. to begin manufacturing and development of its KLTO-202 gene therapy candidate using that company’s cutting-edge AAVone platform technology.

KLTO said working with AAVnerGene “has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current ‘triple transfection’ manufacturing method.”

5. Strong financial footing

On June 16, KLTO announced it had raised $11 million by exercising warrants, and it used $3.1 million of the funds to eliminate all outstanding debt.

Two days later, KLTO said it had terminated a share exchange agreement with SkyBell Technologies which “would have resulted in SkyBell owning 90% of the Company — substantially diluting existing shareholders.” 

“Terminating this agreement allows us to remain focused and build shareholder value while fully concentrating on our core R&D programs,” said KLTO CEO Dr. Joseph Sinkule.

Final Thoughts

KLTO’s promising preclinical results led it on July 25 to announce an expanded focus for the company beyond diseases such as ALS, Alzheimer’s, and Parkinson’s.

It said it is “now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.”

The science of anti-aging has a strong appeal, and it’s not surprising the stock made a move as high as 1,800% after just strong preclinical findings in that space.

This is a company and stock well worth keeping on your radar, especially today following its 10% move on Friday and promising premarket action this morning.

As you do your own research, be sure to review the company website and this January 2025 investor presentation.

And of course, always approach your trading in a responsible manner,  remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from West Coast Media for advertising Klotho Neurosciences, Inc for a one day marketing program starting on August 18, 2025. It might seem obvious, but while our client claims not to own any shares in Klotho Neurosciences, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Klotho Neurosciences, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.